Company intelligence / Profile preview

Umami Bioworks

Singapore, Singaporeumami.is ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

Umami Bioworks has pioneered the use of mesenchymal stem cells from fish to efficiently produce muscle and fat tissues for cultivated seafood. Their continuous production process increases productivity tenfold over traditional batch methods and reduces capital expenditure by sevenfold. The company is preparing for commercial sales less than four years after founding, outpacing first-generation cultivated companies in speed to market with significantly less funding.

Modalities: Cell-based food productionMesenchymal stem cell-derived tissue cultivation
Industry: Non-Drug Biotech

Partnerships

KCell BiosciencesWSG GroupMaruha NichiroSteakholder FoodsFriends and Family Pet Food

Beyond the preview

Go deeper on Umami Bioworks.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Umami Bioworks.

Explore the full profile